10.02.2011 • News • Chris Viehbacher • Chris Viehbacher CEO • Sanofi

Sanofi CEO Says Genzyme Offer May Be Extended

Sanofi Aventis Chief Executive Chris Viehbacher said in an interview that the French pharmaceuticals group's offer for Genzyme could be extended for a third time, beyond the Feb. 15 deadline.

Asked by La Tribune newspaper about the deadline, Viehbacher said: "It is a possibility, there are no limits on takeover offers in the United States."

He added: "It is normal to spend time on an operation of $18.5 billion."

Viehbacher's interview is to be published in La Tribune business newspaper on Thursday and was made available late on Wednesday.

Interview

Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.